EDIT — Editas Medicine Share News
0.000.00%
Last trade - 00:00- $382.41m
- $226.51m
- $40.52m
Brief: Editas Medicine Says Offering Of 12.5 Mln Common Shares Priced At $10.00 per Share
Editas Medicine falls on stock offering plans
Brief: Editas Medicine Announces Offering Of Common Stock
U.S. RESEARCH ROUNDUP-Editas Medicine, First Horizon, Marqeta
U.S. STOCKS ON THE MOVE-Gold miners, ImmunoGen, Oracle
U.S. STOCKS ON THE MOVE-Teekay, gold miners, Oil-Dri Corp
U.S. STOCKS ON THE MOVE-Netflix, Adobe, Carvana
Editas up on positive initial data from blood disorder treatment trials
Brief: Editas Medicine Says Positive Initial Edit-301 Safety And Efficacy Data From First Four Patients Treated In Ruby Trial And First Patient Treated In The Edithal Trial
Brief: Editas Medicine To Host Virtual Event To Discuss Edit-301 Clinical Data For Severe Sickle Cell Disease Trial
Brief: Editas Medicine Announces Appointment Of Erick J. Lucera As Chief Financial Officer
Editas Medicine Inc reports results for the quarter ended in March - Earnings Summary
Brief: Editas Medicine Announces First Quarter 2023 Results And Business Updates
Editas Medicine Inc expected to post a loss of 78 cents a share - Earnings Preview
Editas Medicine Inc expected to post a loss of 78 cents a share - Earnings Preview
Editas Medicine rises on 'orphan drug' tag for sickle cell disease treatment
Brief: Editas Medicine - On March 8, James C. Mullen Notified Board That He Does Not Intend To Seek Re-Election At 2023 Annual Meeting
Brief: Editas Medicine Appoints Linea Aspesi As Chief People Officer
U.S. RESEARCH ROUNDUP-Cinemark Holdings, Commercial Metals Co, Nvidia